[1058156-90-3]    

MFCD29918157

Synonyms : 1-(((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinolin-7-yl)oxy)methyl)cyclopropan-1-amine; Catequentinib; AL 3818

Applications : Anlotinib is a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, anlotininib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.

References : Lin B. et al.: Gene 654, 77-86, 2018; Xie C. et al.: Cancer Sci. 109(4), 1207-1219, 2018; Sun W. et al.: Biomed Res Int., 3619723, 2017; Han B. et al.: Br. J. Cancer., 118(5), 654-661, 2018; Taurin S. et al.: Int. J. Gynecol Cancer 28(1), 152-160, 2018; Sun Y. et al.: J. Hematol Oncol. 9(1), 105, 2016.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.